AbelZeta clinical trials
AbelZeta is the lead sponsor of 3 current clinical trials in our USA register. None of its ClinicalTrials.gov trials is recruiting at the moment. The most common phase is Phase 1/2. The drugs named most often in its trials are C-CAR168 and Prizloncabtagene Autoleucel. The most-studied condition is Multiple Sclerosis.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by AbelZeta
3 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
NCT07825389 · ClinicalTrials.gov ↗ · Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS)
Drug: C-CAR168 |
Phase 1/2 | Not yet open | 2027-02 | USA |
|
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy
NCT07854483 · ClinicalTrials.gov ↗ · Systemic Sclerosis (SSc), Systemic Sclerosis, Systemic Sclerosis (Scleroderma)
Drug: C-CAR168 |
Phase 1 | Not yet open | 2027-03 | USA |
|
Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
NCT07875413 · ClinicalTrials.gov ↗ · Large B Cell Lymphoma, LBCL, Diffuse Large B Cell Lymphoma (DLBCL)
|
Phase 2 | Not yet open | 2027-05 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs in AbelZeta trials
2 compoundsDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in AbelZeta trials
12 conditionsBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 0 |
A trial with sites in more than one country appears in each of those registers.
Other sponsors in Multiple Sclerosis
Sponsors with the most current trials registered for this condition.
Questions about AbelZeta trials
How many clinical trials does AbelZeta sponsor?
AbelZeta is the lead sponsor of 3 current trials on ClinicalTrials.gov in our USA register, as of the registry sync on 16 October 2026. Completed and withdrawn studies are not counted.
Are AbelZeta trials recruiting?
Not at the moment. None of its 3 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Which drugs is AbelZeta testing?
Its current trials name 2 drugs and biologicals as interventions. The most frequent are C-CAR168 (2) and Prizloncabtagene Autoleucel (1). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 16 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.